According to BioMarin Pharmaceutical's latest financial reports the company's current revenue (TTM) is $2.41 B. In 2022 the company made a revenue of $2.09 B an increase over the years 2021 revenue that were of $1.84 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $2.41 B | 15.42% |
2022 | $2.09 B | 13.53% |
2021 | $1.84 B | -0.76% |
2020 | $1.86 B | 9.18% |
2019 | $1.70 B | 14.27% |
2018 | $1.49 B | 13.52% |
2017 | $1.31 B | 17.62% |
2016 | $1.11 B | 25.5% |
2015 | $0.88 B | 18.54% |
2014 | $0.75 B | 36.88% |
2013 | $0.54 B | 9.54% |
2012 | $0.50 B | 13.45% |
2011 | $0.44 B | 17.3% |
2010 | $0.37 B | 15.9% |
2009 | $0.32 B | 9.5% |
2008 | $0.29 B | 143.86% |
2007 | $0.12 B | 44.38% |
2006 | $84.2 M | 228.05% |
2005 | $25.66 M | |
2002 | $13.91 M | 34.65% |
2001 | $10.33 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Sanofi SNY | $50.35 B | 1,981.65% | ๐ซ๐ท France |
Ultragenyx RARE | $0.43 B | -82.05% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $0.17 B | -92.72% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.11 B | -95.19% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.39 B | -83.49% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | $0.39 B | -83.54% | ๐บ๐ธ USA |